IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.860
NA - Nord America 1.507
EU - Europa 734
SA - Sud America 163
AF - Africa 31
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.309
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.595
US - Stati Uniti d'America 1.427
CN - Cina 666
HK - Hong Kong 366
IT - Italia 268
BR - Brasile 115
GB - Regno Unito 111
FR - Francia 91
DE - Germania 90
VN - Vietnam 60
CZ - Repubblica Ceca 54
IN - India 43
MX - Messico 36
CA - Canada 30
FI - Finlandia 26
BD - Bangladesh 21
NL - Olanda 19
ID - Indonesia 15
AR - Argentina 13
ZA - Sudafrica 13
AU - Australia 12
PL - Polonia 11
UA - Ucraina 10
ES - Italia 9
JP - Giappone 9
PH - Filippine 9
PK - Pakistan 9
SA - Arabia Saudita 9
CO - Colombia 8
PY - Paraguay 8
TR - Turchia 8
CL - Cile 7
RU - Federazione Russa 7
TW - Taiwan 7
BE - Belgio 6
IQ - Iraq 6
MY - Malesia 6
CR - Costa Rica 5
EC - Ecuador 5
JO - Giordania 5
PT - Portogallo 5
NP - Nepal 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AT - Austria 3
EE - Estonia 3
GE - Georgia 3
IE - Irlanda 3
LT - Lituania 3
SE - Svezia 3
TN - Tunisia 3
VE - Venezuela 3
AO - Angola 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EG - Egitto 2
JM - Giamaica 2
MA - Marocco 2
MD - Moldavia 2
PE - Perù 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 7.309
Salva come PNG Salva come JPEG
Città #
San Jose 549
Singapore 406
Hong Kong 364
Ashburn 295
Rome 229
Beijing 199
Hefei 184
Boardman 106
London 82
Lauterbourg 79
Dallas 65
Shanghai 61
Munich 48
Brno 35
Los Angeles 35
Council Bluffs 29
Santa Clara 28
San Francisco 26
Mexico City 22
Pune 20
Redmond 20
Ho Chi Minh City 19
Amsterdam 18
Olomouc 17
São Paulo 16
Hanoi 14
New York 14
Turku 14
Seattle 13
Guangzhou 12
Helsinki 11
Washington 11
Manchester 10
Toronto 10
Boston 9
Montreal 8
Nuremberg 8
Orem 8
Tokyo 8
Warsaw 8
Brooklyn 7
Melbourne 6
Rio de Janeiro 6
Campinas 5
Chennai 5
Chicago 5
Frankfurt am Main 5
Haiphong 5
Hangzhou 5
Johannesburg 5
Riyadh 5
San José 5
Amman 4
Ankara 4
Atlanta 4
Biên Hòa 4
Dhaka 4
Haikou 4
Kuala Lumpur 4
Paris 4
Taipei 4
Tashkent 4
Wuhan 4
Brasília 3
Buenos Aires 3
Canberra 3
Colombo 3
Dublin 3
Hanover 3
Hyderabad 3
Jakarta 3
Karachi 3
Milan 3
Mol 3
New Delhi 3
Oklahoma City 3
Stockholm 3
Sydney 3
Tbilisi 3
Tirana 3
Xiamen 3
Asunción 2
Aversa 2
Berlin 2
Bismarck 2
Cairo 2
Caracas 2
Changsha 2
Concord 2
Contagem 2
Curitiba 2
Florence 2
Genoa 2
Grand Rapids 2
Guarujá 2
Hasselt 2
Iowa City 2
Lahore 2
Lisbon 2
Lodz 2
Totale 3.310
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 222
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 206
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 206
Cancer drugs and QT prolongation: weighing risk against benefit 203
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 202
Minimal sampling colistin pharmacokinetics in critically ill patients 201
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 200
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 200
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 194
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 191
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 190
Cardio-oncology in clinical studies and real life 181
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 177
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 160
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 156
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 136
Anthracycline Cardiotoxicity 134
Anthracyclines 124
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 123
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 121
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 120
Anthracycline Cardiotoxicity 109
An introduction to the metabolic determinants of anthracycline cardiotoxicity 101
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 101
Cardiotoxicity of antitumor drugs 99
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 98
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 88
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 86
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 84
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 76
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 74
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 70
Isavuconazole: case report and pharmacokinetic considerations 69
Pharmacology of Cardio-Oncology 65
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 64
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 62
What is cardiotoxicity? 61
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 61
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 60
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 59
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 58
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 58
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 57
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 57
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 55
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 55
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 55
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 52
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 52
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 51
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 51
Pharmacological Foundation of Cardio-Oncology 50
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 50
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 50
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 48
The concomitant management of cancer therapy and cardiac therapy 47
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 46
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 46
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 45
Doxorubicin degradation in cardiomyocytes 43
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 43
Matters of the heart: The case of TNF-alpha targeting drugs 42
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 42
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 41
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 40
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 40
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 40
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 40
Molecular determinants of the reduced cardiotoxicity of epirubicin 40
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 39
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 39
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 39
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 39
The reality of pixantrone in real life 38
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 38
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 38
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 37
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 37
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 37
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 36
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 36
Humans and Rodents: The Case of hOAT4 and mOat5 35
In ®Entresto we trust 35
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 35
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 35
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 35
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 34
Translating molecular mechanisms into clinical facts 34
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 32
Do you know pixantrone? 31
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 31
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 30
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 29
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 29
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 3
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies 2
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 2
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 1
Totale 7.417
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.707
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20262.767 336 204 131 250 139 94 923 205 219 257 9 0
Totale 7.417